Innovus Pharmaceuticals Inc. (fka INNV)

[Honeycomb777]

Shawn - 5m revenue guidance for 2016... This does not include Fluticare and recalmax or any of the new product launches (like Xyralid). Look for q3 to come in at 1.7m or more. As mid November draws closer PPS will rise on FINS excitement alone. That plus the EpiPen saga and how the FDA needs to approve generics more quickly to enhance competition and lower costs bodes very well for us. I will buy the shares you are selling as the timing couldn't be better IMO